# MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma

> **NCT02724020** · PHASE2 · COMPLETED · sponsor: **Millennium Pharmaceuticals, Inc.** · enrollment: 96 (actual)

## Conditions studied

- Clear-cell Metastatic Renal Cell Carcinoma

## Interventions

- **DRUG:** Everolimus
- **DRUG:** MLN0128
- **DRUG:** MLN1117

## Key facts

- **NCT ID:** NCT02724020
- **Lead sponsor:** Millennium Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-06-30
- **Primary completion:** 2020-02-03
- **Final completion:** 2020-10-13
- **Target enrollment:** 96 (ACTUAL)
- **Last updated:** 2021-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02724020

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02724020, "MLN0128 and MLN0128 + MLN1117 Compared With Everolimus in the Treatment of Adults With Advanced or Metastatic Clear-Cell Renal Cell Carcinoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02724020. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*